BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
Indian formulations players’ revenue broadly comprise two segments: (1) branded generics that are sold in countries like India and other emerging markets and generics generics that are sold in the developed markets, mainly the U.S. and EU. Out of the two, we like the Indian branded generics space, due to the following catalysts:
Physician prescription stickiness in brands,
better growth visibility,
lower capex and working capital cycle (working capital ~45 days), and
healthy return ratios, margins and free cash flow.
Other branded generics emerging markets also have similar growth drivers like India, barring currency volatility and country-specific risks.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR